Bianco, Roberto <br/><br/>
Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.  [electronic resource] 

 -  Clinical cancer research : an official journal of the American Association for Cancer Research  Jul 2004 
 - 4858-64 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1078-0432 
<br/><br/><label>Standard No.: </label>10.1158/1078-0432.CCR-03-0497  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Dose-Response Relationship, Drug<br/>Drug Synergism<br/>ErbB Receptors--metabolism<br/>Fibroblast Growth Factor 2--biosynthesis<br/>Gefitinib<br/>Humans<br/>Male<br/>Mice<br/>Mice, Inbred BALB C<br/>Mice, Nude<br/>Mitogen-Activated Protein Kinases--metabolism<br/>Nuclear Proteins--genetics<br/>Oligonucleotides, Antisense--pharmacology<br/>Phosphorylation--drug effects<br/>Prostatic Neoplasms--metabolism<br/>Protein Biosynthesis--drug effects<br/>Protein Serine-Threonine Kinases--metabolism<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins c-akt<br/>Proto-Oncogene Proteins c-mdm2<br/>Quinazolines--pharmacology<br/>Time Factors<br/>Vascular Endothelial Growth Factor A--biosynthesis<br/>Xenograft Model Antitumor Assays